OBJECTIVES: In efforts to obtain complete results, current practice in surgical lung biopsy (LB) for interstitial lung disease (ILD) recommends sending lung tissue samples for bacterial, mycobacterial, fungal, and viral cultures. This study assesses the value of this practice by evaluating the microbiology findings obtained from LB for ILD and their associated costs.
INTRODUCTION
Interstitial lung disease (ILD) is a generic term representing a heterogeneous group of lung diseases classified together because of several common features [1] . Over 100 different pathologies appear in the differential diagnosis of ILD, including certain infectious etiologies [2] . In the stepwise process of ILD diagnosis, surgical lung biopsy remains the last diagnostic procedure. It is requested when the patient's history, physical examination, laboratory studies, radiological findings, and other invasive investigations (bronchoscopy, bronchoalveolar lavage, or trans-bronchial biopsy) have not enabled absolute certainty of diagnosis [3] . In these cases of diagnostic impasse, surgical lung biopsy plays an important role. Given that surgical lung biopsy is the ultimate step in a series of progressively more invasive diagnostic procedures, it has been recommended in an effort to ensure completeness so that, among other tests, the lung tissue obtained be submitted for thorough microbiology testing as well [4] .
Although multiple studies have analyzed the histopathological diagnosis of surgical lung biopsy for ILD, to our knowledge, none has evaluated the clinical yield and cost of the microbiology investigation of surgical lung biopsy for ILD. The present study assesses the yield and cost of routine microbiology testing on surgical lung biopsies obtained to further the diagnosis of patients with ILD.
MATERIALS AND METHODS
From January 2002 to December 2009, 296 consecutive patients underwent surgical lung biopsy with microbiology testing at Mayo Clinic (Rochester, MN, USA) for undifferentiated ILD. All had fragments of lung tissue sent for various microbiology testing. The spectrum of microbiology tests obtained varied among patients. The medical records of all patients were retrospectively retrieved from a prospectively maintained database and reviewed for the purposes of this study. Demographic data, underlying conditions, clinical features, specific diagnostic tests, and their results were reviewed. Preoperative treatments, presumptive diagnosis, postoperative treatments, and clinical considerations regarding each patient's progress were recorded and analyzed. Patients with 'Contaminated' microbiology results were those cases in which the attending physician stated in the postoperative medical record that the microbiology result was a contaminant and this led to no changes in the specific patient's treatment. Patients with 'Pathogenic' micro-organisms were those cases in which the physician stated in the postoperative medical chart that the microbiology result was a pathogenic micro-organism and this resulted in modifications to the specific patient's treatment.
A cost analysis was performed based upon nominal hospital charges adjusted to current United States inflation rates in 2010, as provided by the United States Bureau of Labor Statistics Consumer Price Index data (http://www.bls.gov/home.htm). Cost data included (when performed) cultures, stains, smears, direct fluorescent antibody studies, and microbiologist consulting fees.
This study was approved by the Mayo Foundation Institutional Review Board.
RESULTS
There were 296 patients included in the study. The median age was 61 years (range 18-91 years). There were 156 men (52.7%) and 140 women (47.3%). Twenty-five patients (8.4%) underwent open lung biopsy and 271 (91.6%) had a thoracoscopic lung biopsy. Ninety-day operative mortality occurred in 33 patients (11.1%).
A total of 592 specimens were obtained (range 1-4 per patient). As part of the surgical lung biopsy procedure, all patients had fragments of the biopsied lung tissue sent for histological examination and complete microbiology testing. In 62 patients (21%), there was a preoperative suspicion of infectious disease. Twenty patients (6.7%) were immunosuppressed preoperatively.
The most common pathological diagnoses were idiopathic pulmonary fibrosis in 122 patients (41.2%), cryptogenic organizing pneumonia in 31 patients (10.5%), and respiratory bronchiolitis ILD in 16 patients (5.4%). These data are detailed in Table 1 .
Microbiology testing was negative in 174 patients (58.8%) and positive, indicating an organism was detected in the sample, in 122 cases (41.2%). As many as 118 out of these 122 positive results (96.7%) were clinically considered to be contaminants and resulted in no change in clinical management. The most common organisms were Propionibacterium acnes (n = 60; 36.6%), Penicillium fungus (n = 22; 13.4%), and filamentous fungus (n = 12; 7.3%). These data are detailed in Table 2 . Microbiology testing showed a true positive in only four patients (1.4%). In these cases, the organism cultured (Nocardia one, Histoplasma one, and Aspergillus fumigatus two) resulted in a change of clinical management (addition of specific antibiotic or antifungal drugs to the treatment).
When analyzing the final clinical evaluation of the surgical lung biopsy testing, both histopathology and microbiology tests, the diagnosis of an infectious etiology for the ILD was present in 10 cases (3.4%). In eight cases, the diagnosis was obtained by the morphological description in the pathology report. In six of these cases, special histopathology stains identified an organism. In two of these cases (33%), microbiology cultures were also positive. In two cases, the diagnosis of infectious etiology was exclusively obtained by microbiology cultures (morphological description and special stains had been negative). In all 10 cases of infectious etiology, there was a previous noted clinical suspicion. Four of them were immunosuppressed patients.
The cost of microbiology studies per specimen was $984 (€709). The estimated costs are detailed in Table 3 . The estimated total cost for the whole study cohort was $582 000 (€419 000).
DISCUSSION
ILD, as a diagnostic grouping, encompasses a wide variety of specific diagnoses, including some infectious etiologies. Establishing the cause of ILD can therefore be extremely challenging [5] . Establishing an accurate diagnosis is nevertheless essential so that the patient can be provided with appropriate treatment options and reasonable expectations about the prognosis and effects of therapy [6] .
The ILD diagnosis is obtainable using a stepwise and methodical approach, including progressively more invasive tests, such as trans-bronchial biopsy, transthoracic needle biopsy, and, finally, surgical lung biopsies, either open or thoracoscopic [7] . Generally, lung tissue is still required for the diagnosis of ILD in approximately a third of patients, who do not have a clearly defined environmental exposure or obvious systemic illness involving the lung [8] . The decision to perform a surgical lung biopsy in these patients is based on the likelihood that pathologic examination of the tissue obtained will yield specific information about the cause of the disease process [9] . Several clinical guides recommend routinely sending small fragments of lung tissue from the surgical lung biopsy for bacterial, mycobacterial, fungal, and viral cultures [10, 11] and this has become the common practice in many institutions [3, [12] [13] [14] . Ultimately, this routine practice is understandable, as submitting a minimal sample of the surgical lung biopsy tissue for microbiology studies does not affect the duration of the surgical procedure, the patient recovery, or the histopathologic analysis of the lung tissue. It is seen as extra information for the referring physician, the patient, and his/her family. Our study's findings, however, refute the clinical yield of such a routine practice. In fact, in our study's cohort, only 3.4% of the patients ultimately had an infectious etiology for their ILD. This is in keeping with prior series that show infection to be the cause of ILD in 3-30% of cases [2] . Immunosuppressed patients historically are at an increased risk of having an infectious cause for their ILD [13] . Most importantly however, in our study's patient cohort, the diagnosis of an infectious cause for the ILD was made on the basis of the microbiology testing done on the surgical lung biopsy in only 1.4%. This clinical finding, coupled with the accompanying financial burden of these tests, suggests that the routine use of this form of testing be avoided.
We recognize the limitations of such a retrospective study from a single institution in that there may be inherent biases in the nature of the study design itself. Furthermore, in that infectious etiologies for ILD are subject to geographic influences, we believe it would not be appropriate to speculate on which infectious causes may be most prominent, as this will vary from location to location. The specific potential infectious etiologies are also affected by the individual patient's history and clinical condition.
Nevertheless, surgeons, as part of the multidisciplinary team that is assessing the specific patient with ILD, must actively participate in the diagnostic analysis and evaluate for themselves, with the input of their physician colleagues, which tests are relevant and which are not [15] . Our findings suggest that to routinely obtain microbiology evaluation of lung biopsies in patients with ILD, without assessing the pre-test probability, may result in a poor use of limited medical resources.
We do not, however, believe that there is no role for microbiology testing of surgical lung biopsies obtained in the pursuit of an underlying diagnosis of ILD. We believe that cases with a high level of clinical suspicion of an infectious etiology warrant the use of this form of testing. Targeting patients who are immunosuppressed, or who have objective findings preoperatively of infection, are potential ways of improving the value of this battery of tests. Acknowledging the limited yield of microbiology testing in the overall population of ILD patients, as demonstrated in this study, one should then apply clinical judgment to determine whether, in each individual patient's case, the likelihood of an infectious etiology (pre-test probability) is sufficiently high to warrant the use of microbiology testing. In this way, we can thoughtfully improve the value of these tests for our patients.
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